These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38807111)

  • 1. Cost-effectiveness of drug consumption rooms in France: a modelling study.
    Cousien A; Donadille C; Madrid LB; Maradan G; Jauffret-Roustide M; Lalanne L; Auriacombe M; Roux P; Boyer S
    BMC Public Health; 2024 May; 24(1):1426. PubMed ID: 38807111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drug Consumption Rooms : Opinion and willingness among people who inject drugs in Marseille, France].
    Briand Madrid L; Donadille C; Célerier I; Gutowski M; Grelli N; Maradan G; Jauffret-Roustide M; Lalanne L; Auriacombe M; Roux P;
    Rev Epidemiol Sante Publique; 2023 Feb; 71(1):101421. PubMed ID: 36571957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of drug consumption rooms on non-fatal overdoses, abscesses and emergency department visits in people who inject drugs in France: results from the COSINUS cohort.
    Roux P; Jauffret-Roustide M; Donadille C; Briand Madrid L; Denis C; Célérier I; Chauvin C; Hamelin N; Maradan G; Carrieri MP; Protopopescu C; Lalanne L; Auriacombe M;
    Int J Epidemiol; 2023 Apr; 52(2):562-576. PubMed ID: 35690956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of drug consumption rooms on risk practices and access to care in people who inject drugs in France: the COSINUS prospective cohort study protocol.
    Auriacombe M; Roux P; Briand Madrid L; Kirchherr S; Kervran C; Chauvin C; Gutowski M; Denis C; Carrieri MP; Lalanne L; Jauffret-Roustide M;
    BMJ Open; 2019 Feb; 9(2):e023683. PubMed ID: 30796121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
    J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health outcomes and cost-effectiveness of diversion programs for low-level drug offenders: A model-based analysis.
    Bernard CL; Rao IJ; Robison KK; Brandeau ML
    PLoS Med; 2020 Oct; 17(10):e1003239. PubMed ID: 33048929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug consumption rooms are effective to reduce at-risk practices associated with HIV/HCV infections among people who inject drugs: Results from the COSINUS cohort study.
    Lalanne L; Roux P; Donadille C; Briand Madrid L; Célerier I; Chauvin C; Hamelin N; Kervran C; Maradan G; Auriacombe M; Jauffret-Roustide M;
    Addiction; 2024 Jan; 119(1):180-199. PubMed ID: 37743675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
    Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
    Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England.
    Ward Z; Reynolds R; Campbell L; Martin NK; Harrison G; Irving W; Hickman M; Vickerman P
    Addiction; 2020 Aug; 115(8):1509-1521. PubMed ID: 31984606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO-HCV trial.
    Lim AG; Aas CF; Çağlar ES; Vold JH; Fadnes LT; Vickerman P; Johansson KA
    Addiction; 2023 Dec; 118(12):2424-2439. PubMed ID: 37515462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of the effect of needle and syringe programs on skin, soft tissue, and vascular infections in people who inject drugs: a microsimulation modelling approach.
    Lim J; Russell WA; El-Sheikh M; Buckeridge DL; Panagiotoglou D
    Harm Reduct J; 2024 Jun; 21(1):126. PubMed ID: 38943164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada.
    Enns EA; Zaric GS; Strike CJ; Jairam JA; Kolla G; Bayoumi AM
    Addiction; 2016 Mar; 111(3):475-89. PubMed ID: 26616368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug consumption rooms in Catalonia: A comprehensive evaluation of social, health and harm reduction benefits.
    Folch C; Lorente N; Majó X; Parés-Badell O; Roca X; Brugal T; Roux P; Carrieri P; Colom J; Casabona J;
    Int J Drug Policy; 2018 Dec; 62():24-29. PubMed ID: 30352331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs.
    Barbosa C; Fraser H; Hoerger TJ; Leib A; Havens JR; Young A; Kral A; Page K; Evans J; Zibbell J; Hariri S; Vellozzi C; Nerlander L; Ward JW; Vickerman P
    Addiction; 2019 Dec; 114(12):2267-2278. PubMed ID: 31307116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.
    Scott N; McBryde ES; Thompson A; Doyle JS; Hellard ME
    Gut; 2017 Aug; 66(8):1507-1515. PubMed ID: 27196586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities.
    Krebs E; Zang X; Enns B; Min JE; Behrends CN; Del Rio C; Dombrowski JC; Feaster DJ; Gebo KA; Marshall BDL; Mehta SH; Metsch LR; Pandya A; Schackman BR; Strathdee SA; Nosyk B;
    J Infect Dis; 2020 Sep; 222(Suppl 5):S301-S311. PubMed ID: 32877548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis.
    Bernard CL; Owens DK; Goldhaber-Fiebert JD; Brandeau ML
    PLoS Med; 2017 May; 14(5):e1002312. PubMed ID: 28542184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of geographical areas in France, ANRS-Coquelicot 2011 survey.
    Weill-Barillet L; Pillonel J; Semaille C; Léon L; Le Strat Y; Pascal X; Barin F; Jauffret-Roustide M
    Rev Epidemiol Sante Publique; 2016 Sep; 64(4):301-12. PubMed ID: 26904917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High willingness to use drug consumption rooms among people who inject drugs in Scotland: findings from a national bio-behavioural survey among people who inject drugs.
    Trayner KMA; Palmateer NE; Hutchinson SJ; Goldberg DJ; Shepherd SJ; Gunson RN; Tweed EJ; Priyadarshi S; Sumnall H; Atkinson A; McAuley A
    Int J Drug Policy; 2021 Apr; 90():102731. PubMed ID: 32331859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.